SurgeCare

📍 Paris, France🗓 Founded 2022👥 24 employees💰 Last funded Jul 2024
Hospitals and Health Care🌐 surge.care
Website LinkedIn
Surge develops PreCyte, an immune-based diagnostic approach to identify patients at risk of postoperative complications and support smarter discharge and care pathways. PreCyte focuses on immune signatures associated with surgical site infection and pulmonary complications, helping care teams intervene earlier and allocate resources more effectively. Use cases - Postoperative risk stratification for surgical site infection and pulmonary complications - Support for discharge timing and pathway optimization in perioperative care - Immune profiling to inform patient monitoring and follow-up decisions Proof points - Early clinical deployments with leading academic medical centers - Built on more than a decade of translational immunology and multi-omics research - Developed with a strong focus on quality, clinical proofpoints, and technological breakthroughs
3
Total investors
0
Early stage
3
Mid stage
0
Late stage
2022
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
3
Frequently asked questions
Who invested in SurgeCare?
SurgeCare has 3 investors on record on gritt.io, 3 mid-stage.
When did SurgeCare last raise funding?
The most recent investment in SurgeCare recorded on gritt.io was in July 2024.
When was SurgeCare founded?
SurgeCare was founded in 2022.
What industry is SurgeCare in?
SurgeCare operates in Hospitals and Health Care. Find similar Hospitals and Health Care investors on gritt.io.
Where is SurgeCare based?
SurgeCare is headquartered in Paris, France.